Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis-Reference-Cited by-同舟云学术

Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis

Published:2015-09-04 Issue:12 Volume:262 Page:2627-2634
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Montalban Xavier,Comi Giancarlo,Antel Jack,O’Connor Paul,de Vera Ana,Cremer Malika,Sfikas Nikolaos,von Rosenstiel Philipp,Kappos Ludwig

Publisher

Springer Science and Business Media LLC

Subject

Clinical Neurology,Neurology

Link

http://link.springer.com/content/pdf/10.1007/s00415-015-7834-0.pdf

Reference19 articles.

1. European Medicines Agency (2011) Annex I. Summary of product characteristics. Gilenya (fingolimod). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf . Accessed 10 June 2015

2. US Food and Drug Administration (2015) Gilenya full prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022527s013lbl.pdf . Accessed 9 June 2014

3. Novartis Q1 2015 condensed interim financial report. https://www.novartis.com/sites/www.novartis.com/files/2015-04-interim-financial-report-en.pdf . Accessed 10 June 2015

4. Beck AT, Steer RA (1978) Beck Depression Inventory. The Psychological Corporation Harcourt Brace Jovanovich, Inc

5. Bermel RA, Bakshi R (2006) The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 5:158–170

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. External Validation of the Budget Impact Analysis of the Drug Fingolimode in the Treatment of Multiple Sclerosis;2024-07-02

2. Immunopathogenesis of multiple sclerosis: molecular and cellular mechanisms and new immunotherapeutic approaches;Immunopharmacology and Immunotoxicology;2024-04-18

3. Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis;Neurology;2022-06-06

4. Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data;Psychopharmacology;2021-11-13

5. Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis;Multiple Sclerosis Journal;2020-09-25